Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

• Published in: Value in health 2012-12, Vol.15 (8), p.1162-1171
• Main Authors: Faulkner, Eric, MPH, Annemans, Lieven, PhD, MSc, Garrison, Lou, PhD, Helfand, Mark, MD, MPH, Holtorf, Anke-Peggy, PhD, MBA, Hornberger, John, MD, MS, Hughes, Dyfrig, PhD, MRPharmS, Li, Tracy, PhD, Malone, Daniel, PhD, Payne, Katherine, PhD, Siebert, Uwe, MD, MPH, MSc, ScD, Towse, Adrian, MA, Veenstra, David, PhD, PharmD, Watkins, John, PharmD, MPH, BCPS
• Format: Article
• Language: English
• Subjects: Best practice; Biomedical Research; diagnostics; Drug Industry - economics; Drug Industry - organization & administration; Economics, Pharmaceutical; Health; Health economics; health economics and outcomes research; Health Services Accessibility - economics; Health status; health technology assessment; Humans; Individualized; Insurance, Health, Reimbursement - statistics & numerical data; Internal Medicine; Medical research; Outcome Assessment (Health Care) - economics; Outcome Assessment (Health Care) - methods; personalized medicine; Pharmacogenetics; Precision Medicine - economics; Precision Medicine - methods; reimbursement; Technology Assessment, Biomedical
• ISSN: 1098-3015; 1524-4733
• DOI: 10.1016/j.jval.2012.05.006

Abstract Background Personalized medicine technologies can improve individual health by delivering the right dose of the right drug to the right patient at the right time but create challenges in deciding which technologies offer sufficient value to justify widespread diffusion. Personalized medicine technologies, however, do not neatly fit into existing health technology assessment and reimbursement processes. Objectives In this article, the Personalized Medicine Special Interest Group of the International Society for Pharmacoeconomics and Outcomes Research evaluated key development and reimbursement considerations from the payer and manufacturer perspectives. Methods Five key areas in which health economics and outcomes research best practices could be developed to improve value assessment, reimbursement, and patient access decisions for personalized medicine have been identified. Results These areas are as follows: 1 research prioritization and early value assessment, 2 best practices for clinical evidence development, 3 best practices for health economic assessment, 4 addressing health technology assessment challenges, and 5 new incentive and reimbursement approaches for personalized medicine. Conclusions Key gaps in health economics and outcomes research best practices, decision standards, and value assessment processes are also discussed, along with next steps for evolving health economics and outcomes research practices in personalized medicine.